Orchid Pharma Limited (ORCHPHARMA.NS)
INR 1794.0
(0.9%)
INR 1794.0
(0.9%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -1.31 Billion INR | -142.55% |
| 2022 | 3.08 Billion INR | 17.11% |
| 2021 | 2.63 Billion INR | -39.68% |
| 2020 | 4.37 Billion INR | -7.8% |
| 2019 | 4.74 Billion INR | -84.89% |
| 2018 | 31.37 Billion INR | -0.92% |
| 2017 | 31.66 Billion INR | 11.15% |
| 2016 | 28.49 Billion INR | -1.74% |
| 2015 | 28.99 Billion INR | 5.44% |
| 2014 | 27.5 Billion INR | -13.54% |
| 2013 | 31.8 Billion INR | 0.0% |
| 2011 | 18.26 Billion INR | 64.62% |
| 2010 | 11.09 Billion INR | 58.34% |
| 2009 | 7 Billion INR | -60.45% |
| 2008 | 17.71 Billion INR | 52.92% |
| 2007 | 11.58 Billion INR | 70.97% |
| 2006 | 6.77 Billion INR | -34.13% |
| 2005 | 10.28 Billion INR | 5.03% |
| 2004 | 9.79 Billion INR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | - INR | 100.0% |
| 2023 Q1 | 266.11 Million INR | -91.38% |
| 2023 FY | -1.31 Billion INR | -142.55% |
| 2023 Q2 | 1.06 Billion INR | 301.95% |
| 2023 Q3 | 503.63 Million INR | -52.92% |
| 2023 Q4 | -1.31 Billion INR | -360.87% |
| 2022 Q2 | 3.34 Billion INR | 7661.73% |
| 2022 Q4 | 3.08 Billion INR | 2333.18% |
| 2022 FY | 3.08 Billion INR | 17.11% |
| 2022 Q3 | 126.89 Million INR | -96.21% |
| 2022 Q1 | 43.12 Million INR | -98.36% |
| 2021 Q1 | 315.14 Million INR | -92.79% |
| 2021 FY | 2.63 Billion INR | -39.68% |
| 2021 Q4 | 2.63 Billion INR | 1181.6% |
| 2021 Q3 | 205.71 Million INR | -92.74% |
| 2021 Q2 | 2.83 Billion INR | 798.92% |
| 2020 Q2 | 4.19 Billion INR | 138.66% |
| 2020 Q3 | 641.96 Million INR | -84.71% |
| 2020 Q4 | 4.37 Billion INR | 580.8% |
| 2020 FY | 4.37 Billion INR | -7.8% |
| 2020 Q1 | 1.75 Billion INR | -62.89% |
| 2019 FY | 4.74 Billion INR | -84.89% |
| 2019 Q4 | 4.74 Billion INR | 0.0% |
| 2019 Q1 | 3.28 Billion INR | 0.0% |
| 2018 FY | 31.37 Billion INR | -0.92% |
| 2018 Q2 | 23.63 Billion INR | 0.0% |
| 2017 FY | 31.66 Billion INR | 11.15% |
| 2016 FY | 28.49 Billion INR | -1.74% |
| 2015 FY | 28.99 Billion INR | 5.44% |
| 2014 FY | 27.5 Billion INR | -13.54% |
| 2013 FY | 31.8 Billion INR | 0.0% |
| 2013 Q2 | 24.03 Billion INR | 0.0% |
| 2011 FY | 18.26 Billion INR | 64.62% |
| 2011 Q4 | 18.26 Billion INR | 0.0% |
| 2010 FY | 11.09 Billion INR | 58.34% |
| 2009 FY | 7 Billion INR | -60.45% |
| 2008 FY | 17.71 Billion INR | 52.92% |
| 2007 FY | 11.58 Billion INR | 70.97% |
| 2006 FY | 6.77 Billion INR | -34.13% |
| 2005 FY | 10.28 Billion INR | 5.03% |
| 2004 FY | 9.79 Billion INR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Sigachi Industries Limited | 859.94 Million INR | 252.782% |
| Ind-Swift Limited | 9.5 Billion INR | 113.817% |
| Bajaj HealthCare Limited | 3.29 Billion INR | 139.826% |
| Sakar Healthcare Limited | 790.93 Million INR | 266.112% |
| Aurobindo Pharma Limited | 3.69 Billion INR | 135.574% |
| Innova Captab Limited | 2.33 Billion INR | 156.297% |
| Divi's Laboratories Limited | -39.77 Billion INR | 96.696% |
| AstraZeneca Pharma India Limited | -5.01 Billion INR | 73.788% |
| Morepen Laboratories Limited | -231.17 Million INR | -468.336% |
| Mankind Pharma Limited | -1.74 Billion INR | 24.852% |
| Sequent Scientific Limited | 4.17 Billion INR | 131.442% |
| Wanbury Limited | 1.1 Billion INR | 218.806% |
| Laurus Labs Limited | 24.35 Billion INR | 105.394% |
| Nectar Lifesciences Limited | 6.15 Billion INR | 121.338% |
| Glenmark Life Sciences Limited | -2.84 Billion INR | 53.781% |
| Alembic Limited | 66.9 Million INR | 2063.894% |
| Hikal Limited | 7.96 Billion INR | 116.491% |
| Alembic Pharmaceuticals Limited | 3.86 Billion INR | 133.985% |
| Neuland Laboratories Limited | -214.05 Million INR | -513.78% |
| J. B. Chemicals & Pharmaceuticals Limited | 2.82 Billion INR | 146.57% |
| Glenmark Pharmaceuticals Limited | -4.28 Billion INR | 69.34% |
| IOL Chemicals and Pharmaceuticals Limited | -1.1 Billion INR | -19.299% |
| Themis Medicare Limited | 764.96 Million INR | 271.753% |
| RPG Life Sciences Limited | -364.7 Million INR | -260.254% |
| Zydus Lifesciences Limited | 3.91 Billion INR | 133.585% |
| Lupin Limited | 19.38 Billion INR | 106.778% |
| Amrutanjan Health Care Limited | -248.79 Million INR | -428.09% |
| Wockhardt Limited | 18.27 Billion INR | 107.191% |
| Vaishali Pharma Limited | 119.13 Million INR | 1202.82% |
| Aarti Pharmalabs Limited | 2.61 Billion INR | 150.302% |
| Jagsonpal Pharmaceuticals Limited | -1.38 Billion INR | 5.474% |
| Jubilant Pharmova Limited | 27.07 Billion INR | 104.853% |
| FDC Limited | -57.75 Million INR | -2174.977% |
| Dr. Reddy's Laboratories Limited | 12.91 Billion INR | 110.175% |
| Kilitch Drugs (India) Limited | 120.03 Million INR | 1194.515% |
| Eris Lifesciences Limited | 13.8 Billion INR | 109.516% |
| Venus Remedies Limited | -267.7 Million INR | -390.79% |
| ZIM Laboratories Limited | 983.6 Million INR | 233.575% |
| Bliss GVS Pharma Limited | -1.15 Billion INR | -13.482% |
| Par Drugs and Chemicals Limited | -366.53 Million INR | -258.446% |
| Caplin Point Laboratories Limited | -5.5 Billion INR | 76.145% |
| Shilpa Medicare Limited | 9.06 Billion INR | 114.486% |
| Albert David Limited | -278.36 Million INR | -371.98% |
| Ajanta Pharma Limited | -954.9 Million INR | -37.59% |
| Hester Biosciences Limited | 2.29 Billion INR | 157.355% |
| Suven Pharmaceuticals Limited | 144.97 Million INR | 1006.25% |
| Solara Active Pharma Sciences Limited | 10.03 Billion INR | 113.097% |
| Gufic Biosciences Limited | 3.19 Billion INR | 141.131% |
| Windlas Biotech Limited | -273.04 Million INR | -381.191% |
| Procter & Gamble Health Limited | -2.34 Billion INR | 44.044% |
| Aarey Drugs & Pharmaceuticals Limited | 297.57 Million INR | 541.511% |
| Mangalam Drugs & Organics Limited | 975.81 Million INR | 234.641% |
| Granules India Limited | 9.28 Billion INR | 114.147% |
| Aarti Drugs Limited | 5.54 Billion INR | 123.68% |
| Bal Pharma Limited | 1.26 Billion INR | 203.98% |
| Alkem Laboratories Limited | -1.6 Billion INR | 18.364% |
| Sun Pharmaceutical Industries Limited | -72.47 Billion INR | 98.187% |
| Lincoln Pharmaceuticals Limited | -127.63 Million INR | -929.353% |
| Medicamen Biotech Limited | 160.31 Million INR | 919.535% |
| Unichem Laboratories Limited | 931.91 Million INR | 240.983% |
| Bafna Pharmaceuticals Limited | 229.93 Million INR | 671.403% |
| Biofil Chemicals and Pharmaceuticals Limited | -18.44 Million INR | -7022.655% |
| Valiant Laboratories Limited | 649.9 Million INR | 302.16% |
| Medico Remedies Limited | 78.67 Million INR | 1769.923% |
| Ind-Swift Laboratories Limited | -4.15 Billion INR | 68.364% |
| Ipca Laboratories Limited | 11.41 Billion INR | 111.51% |
| Brooks Laboratories Limited | 49.48 Million INR | 2755.037% |
| Syncom Formulations (India) Limited | 46.21 Million INR | 2943.143% |
| Piramal Enterprises Limited | 491.39 Billion INR | 100.267% |
| Torrent Pharmaceuticals Limited | 31.83 Billion INR | 104.128% |
| NATCO Pharma Limited | -5.81 Billion INR | 77.414% |
| Suven Life Sciences Limited | -1.63 Billion INR | 19.529% |
| Krebs Biochemicals & Industries Limited | 1.93 Billion INR | 167.972% |
| Strides Pharma Science Limited | 23.25 Billion INR | 105.649% |
| Indoco Remedies Limited | 6.47 Billion INR | 120.287% |
| Alpa Laboratories Limited | 35.36 Million INR | 3815.31% |
| Lasa Supergenerics Limited | 205.79 Million INR | 738.412% |
| Sun Pharma Advanced Research Company Limited | -941.8 Million INR | -39.504% |